Innovo Mimetics specializes in anti-cancer therapy efficacy assays in the well-established chick egg tumor xenograft model. This model is based on the ability of a fertilized chick egg to engraft and nourish foreign cells, including cancer cells, that are placed in the egg.
Innovo's proprietary assay system, ScreenOvo, allows rapid and low-cost evaluation of chemical, biological, and cell therapies. The advantages of the ScreenOvo Assay include a living tumor at low cost; a complete assay in 14 days; and broad applicability for testing immune cell therapies, checkpoint inhibition, and anti-cancer drug efficacy.
ScreenOvo is designed as a service tool for immunotherapy and pharmaceutical companies to deliver xenograft tumor data in the chick egg model in order to expand the cancer therapy pipeline, generate proofs of concept for new innovations, screen for lead products, and reduce research risk before heavily investing in mouse models.
ScreenOvo offers cancer cell recognition and killing, tumor infiltration, antibody-dependent cellular cytotoxicity, and checkpoint inhibition.